ABUS
Arbutus Biopharma Corporation
ABUS offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
LLY
Eli Lilly and Company
LLY has the edge over ABUS overall, supported by stronger modeled upside and stronger valuation.
ABUS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Unavailable |
ABUS's revenue, profitability and cash flow are currently healthy. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ABUS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 3.6x | $4.03 | — |
| Cheap | 5.2x | $5.83 | +45% |
| Fair | 5.5x | $6.20 | +54% |
| Expensive | 6.3x | $7.07 | +75% |
Historical ranges are pointers, not guarantees.
ABUS has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ABUS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect ABUS's losses to shrink, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ABUS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $1.13 | +$1.36 |
| Q2 2026 | $0.79 | +$1.08 |
| Q1 2026 | $0.83 | +$1.24 |
| Q4 2025 | -$0.17 | +$0.21 |
| Q3 2025 | -$0.23 | +$0.20 |
| Q2 2025 | -$0.29 | +$0.16 |
| Q1 2025 | -$0.41 | +$0.03 |
| Q4 2024 | -$0.38 | +$0.06 |
ABUS has returned to profit: it earned $1.13 per share over the past year, after losing money the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
ABUS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $299K | -43% |
| Q2 2026 | $1M | -91% |
| Q1 2026 | $179.1M | +10055% |
| Q4 2025 | $1.1M | -33% |
| Q3 2025 | $529K | -60% |
| Q2 2025 | $10.7M | +522% |
| Q1 2025 | $1.8M | +15% |
| Q4 2024 | $1.6M | -27% |
ABUS's revenue is growing: $299,000 last quarter, down 43% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3510% | -1873 points |
| Q2 2026 | -588% | -602 points |
| Q1 2026 | 94% | +1551 points |
| Q4 2025 | -503% | +382 points |
| Q3 2025 | -1637% | -36 points |
| Q2 2025 | 14% | +1264 points |
| Q1 2025 | -1457% | -193 points |
| Q4 2024 | -885% | +82 points |
ABUS's operating margin was −3510% last quarter, down 1873 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ABUS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ABUS on profitability, with a higher operating margin.
ABUS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $239.8M | +$245.6M |
| Q2 2026 | -$6M | +$9.7M |
| Q1 2026 | -$8.1M | +$5.3M |
| Q4 2025 | -$4.7M | +$5.7M |
| Q3 2025 | -$5.8M | +$14.9M |
| Q2 2025 | -$15.7M | -$1.2M |
| Q1 2025 | -$13.4M | +$6M |
| Q4 2024 | -$10.4M | +$6.9M |
ABUS has the edge over LLY on cash flow, with more consistent year-over-year improvement.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
ABUS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.1% | +2.2M shares |
| 1 year | +4.1% | +7.8M shares |
| 3 years | +19% | +32.1M shares |
| 5 years | +106% | +103M shares |
| Available history | +190% | +131M shares |
ABUS has 200M diluted shares, up 4.1% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ABUS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ABUS Net Leverage
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ABUS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.0 | Neutral |
| Stochastic | 12.4 | Oversold |
ABUS's weekly RSI is 42 (neutral) and its Stochastic is 12 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ABUS PE vs Healthcare Sector
| Metric | ABUS | Sector median | Relative |
|---|---|---|---|
| PE | 3.6x | 26x | 86% below |
| PE % | 0 | 29 | 29 pts below |
ABUS has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ABUS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.23 | 4.7% below |
| 20 week MA | $4.58 | 12% below |
| 50 week MA | $4.45 | 9.4% below |
| 100 week MA | $4.03 | 0% above |
| 200 week MA | $3.43 | 17% above |
ABUS has fallen below most of its moving averages, though it's still 17% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ABUS on trend strength, trading above more of its moving averages.
ABUS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.49 | $3.87 | +55% |
| 2021 | $3.87 | $4.16 | +7.5% |
| 2022 | $4.16 | $2.39 | -43% |
| 2023 | $2.39 | $2.50 | +4.6% |
| 2024 | $2.50 | $3.21 | +28% |
| 2025 | $3.21 | $4.78 | +49% |
| 2026 YTD | $4.78 | $4.03 | -16% |
ABUS has finished higher in five of the last six years. It's down 16% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ABUS on returns for 2026, with the stronger performance.